Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Debt (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Debt for 3 consecutive years, with $8.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt changed N/A to $8.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a N/A change, with the full-year FY2022 number at $10.2 million, changed N/A from a year prior.
  • Total Debt was $8.3 million for Q3 2025 at Century Therapeutics, down from $10.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $10.3 million in Q1 2023 to a low of $8.3 million in Q3 2025.
  • A 3-year average of $9.9 million and a median of $10.1 million in 2022 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 2.78% in 2023; the steepest drop was 2.78% in 2023.
  • Century Therapeutics' Total Debt stood at $10.2 million in 2022, then rose by 0.55% to $10.3 million in 2023, then decreased by 19.02% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Total Debt are $8.3 million (Q3 2025), $10.3 million (Q1 2023), and $10.2 million (Q4 2022).